IRB/UVA Tracking #
21775
Principal Investigator
Stephen H Caldwell
Contact
Jennifer Greene
Contact Email
Contact Phone
434.982.0709
Official Trial Title
A Phase 3, Multinational, Double Blind, Randomised, Placebo Controlled Study of MGL-3196 (resmetiron) in Patients with Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/0r Hepatic Decompensation
Study Description
The department of hepatology seeks adults over 18 with NASH (fatty liver disease) for a research study. The purpose of the study is to determine the safest dose of resmetirom, a new drug to treat NASH and prevent complications.
You may be eligible for this study if you have fatty liver disease and are willing to come to UVA for study visits.
Study involves up to 30 visits to UVA over 4.5 years, at least 2 extra liver biopsies, 3 MRI scans, 3 DXA scans, 5 fibroscans, EKGs throughout the study and taking an unapproved medication daily.
Study-related insert exams, tests and experimental medication provided free of charge.
Compensation
You will be paid $75 for each visit that you complete.